Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

liver, lung and lymph node metastases. The duration of response, independently reviewed, ranged from 7.1 weeks to 30.0 weeks. The median time to progression in the treated population was 5.9 weeks. The adverse events were manageable, predictable and consistent with those seen in the Phase I trials of ispinesib. The most common grade 3/4 adverse events observed were neutropenia, febrile neutropenia and neutropenic sepsis.

In addition, GSK has sponsored three dose-escalating Phase Ib clinical trials. Each of these clinical trials was designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib in combination with a leading anti-cancer therapeutic, one in combination with carboplatin, the second in combination with capecitabine, and the third in combination with docetaxel. The clinical trial evaluating ispinesib in combination with capecitabine is closed to enrollment. Final data from this trial are expected in 2007.

Under a November 2006 amendment to its collaboration and license agreement with GSK, Cytokinetics has assumed responsibility for the costs and activities associated with the continued development of the KSP inhibitors, ispinesib and SB-743921, subject to GSK s option to resume responsibility for some or all development and commercialization activities associated with each of these novel drug candidates. Cytokinetics plans to conduct, at its expense, a focused development program for ispinesib in breast cancer specifically designed to supplement the broad series of Phase I and Phase II clinical trials sponsored by GSK that have demonstrated clinical activity in the treatment of patients with metastatic breast cancer and that have shown an acceptable tolerability profile for ispinesib in combination with standard chemotherapeutics.

The NCI has sponsored six additional Phase II clinical trials, evaluating the potential efficacy of ispinesib in an array of different tumor types. Enrollment has been closed for
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:5/27/2015)... N.Y. , May 27, 2015  VirtualScopics, ... of clinical trial imaging solutions, announced today, ahead ... Medicine (ISMRM) Annual Meeting in Toronto ... operational investments in Magnetic Resonance Elastography (MRE).  VirtualScopics, ... supporting pharmaceutical companies integrating MRE into their global, ...
(Date:5/27/2015)... LONDON and NEW YORK ... - http://www.abmrg.com/Indonesia-Respiratory-Devices-and-Respiratory-Diagnostics-Market-through-2020---Detailed-analysis-of-Hospital-and-Retail-market.html - Over 70% Indonesian ... Around 400,000 Indonesians die annually due to smoking-related conditions; ... Three-fourths of 6.5 million vehicles in Jakarta ... Indonesia is the fourth ...
(Date:5/27/2015)... N.J. , May 27, 2015  Cambrex Corporation (NYSE: ... , Executive Vice President and Chief Financial Officer, will present ... 2015 at 8:00 a.m. EDT in New York ... slide presentation can be accessed from the Cambrex website at ... Presentations", and a replay will be available for 90 days ...
Breaking Medicine Technology:VirtualScopics, Inc. Makes Investments In Magnetic Resonance Elastography (MRE) 2VirtualScopics, Inc. Makes Investments In Magnetic Resonance Elastography (MRE) 3VirtualScopics, Inc. Makes Investments In Magnetic Resonance Elastography (MRE) 4Indonesia Respiratory Devices Market is Expected to Grow at a CAGR of 9% - Boosting Growth for Respiratory Disposables 2Indonesia Respiratory Devices Market is Expected to Grow at a CAGR of 9% - Boosting Growth for Respiratory Disposables 3Indonesia Respiratory Devices Market is Expected to Grow at a CAGR of 9% - Boosting Growth for Respiratory Disposables 4
... Calif., Oct. 6 PRO-DEX, INC. (Nasdaq: PDEX ... as Chief Financial Officer, effective October 6, 2010.  Mr. Hurwitz ... "Hal comes to Pro-Dex with a broad financial background ... with Coopers & Lybrand LLP, now part of PricewaterhouseCoopers LLP, ...
... DiFUSION Technologies Inc., a medical device company focused ... CleanFUZE™ anti-microbial technology for orthopedic implants, announced today ... of posterior interbody devices indicated for intervertebral body ... SI, in skeletally mature patients who have had ...
Cached Medicine Technology:Pro-Dex, Inc. Appoints Harold A. Hurwitz as Chief Financial Officer 2DiFUSION Technologies Receives 510(k) Clearance of Xiphos™ Interbody Implants for Spinal Fusion 2
(Date:5/27/2015)... May 27, 2015 SAN DIEGO, ... Gulfport Mississippi, is the first healthcare provider along ... to chronic care management (CCM). In partnership with ... is introducing RevUp, a new program that enables ... and increase monthly reimbursements. This new, user-friendly program ...
(Date:5/27/2015)... May 27, 2015 Coco Libre announced today ... able to reach for Organic Coconut Water to quench their ... be available at VIP areas, artist greenrooms, corporate skyboxes and ... at area hotels and on festival shuttle buses. , ... year,” said Noa Elan, Director of Strategic Partnerships for Latitude ...
(Date:5/27/2015)... 27, 2015 This is a ... of the Omega-3 industry. The report provides a ... applications and industry chain structure. The Omega-3 market ... development trends, competitive landscape analysis, and key regions ... Camanchaca Fishing Company, Seadragon Marine Oils, Norwegian Fish ...
(Date:5/27/2015)... With InnerVoice Communication App you will ... is not only heard but seen -- by a photograph ... image. This award-winning and affordable app takes full advantage of ... InnerVoice Sender app in conjunction with InnerVoice Communication ... remotely for no additional cost. , InnerVoice Sender ...
(Date:5/27/2015)... For a limited time, San Fernando ... discounts on facial fillers. Skin loses more than 2 percent ... This lost collagen can lead to thinning or sagging skin, ... Facial fillers are an excellent way to plump skin and ... to create a softer and more youthful appearance, without the ...
Breaking Medicine News(10 mins):Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 3Health News:Coco Libre Puts Organic Coconut Water on the Line-up at BottleRock Napa 2Health News:Omega-3 Market: Global 2015 Analysis & 2020 Forecasts on Market Size 2Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 2Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 3Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 4Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Discounts on Facial Fillers 2
... Announced the Initiation of the Phase III ... to Treat Rheumatoid Arthritis., COPENHAGEN, Denmark, November 20 ... GSK) announced today the,initiation of the Phase III program ... commence with two studies,(GEN410/OFA110635 and GEN411/OFA110634) which will be ...
... November 20 With the recent,FDA approval of ... and follow-up of cancerous or other potentially malignant,lesions ... Technologies,succeeds in setting the trend in diagnostic oncology ... Lesion Management Solutions at the,93rd annual meeting of ...
... Nov. 16 For patients with,rheumatoid arthritis, combining one ... medications often works best to reduce joint,swelling or tenderness, ... for,Healthcare Research and Quality, part of the U.S. Department ... report will be posted on-line,Monday in the Annals of ...
... 19 If you or someone you know,has been ... or medical,personnel working with lung cancer patients, you won,t ... Advocacy Conference. The conference,co-presented by the American Lung Association ... be held Friday, Nov. 30, at the,Ritz-Carlton Dearborn. Medical ...
... healthy individuals, have made a key discovery in understanding ... and remain untreated by the bodys own natural defences. ... 23 November) by the Proceedings of the National Academy ... , Under normal circumstances, the immune system creates ...
... studies suggest , , MONDAY, Nov. 19 (HealthDay News) -- People ... and dementia as they age, two new studies suggest. ... pressure increased the risk of developing disabilities, such as not ... or bathe oneself. , "High blood pressure affects many ...
Cached Medicine News:Health News:Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program 2Health News:Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program 3Health News:Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program 4Health News:MEDIAN Technologies Lesion Management Solutions Set the Trend in Diagnostic Oncology Imaging at RSNA 2007 2Health News:Combining Medications Often Best Strategy to Battle Rheumatoid Arthritis 2Health News:Combining Medications Often Best Strategy to Battle Rheumatoid Arthritis 3Health News:BREATHE Lung Cancer Conference, Nov. 30, Offers Medical and Patient Education, Advocacy and Survivor's Perspective 2Health News:BREATHE Lung Cancer Conference, Nov. 30, Offers Medical and Patient Education, Advocacy and Survivor's Perspective 3Health News:BREATHE Lung Cancer Conference, Nov. 30, Offers Medical and Patient Education, Advocacy and Survivor's Perspective 4Health News:BREATHE Lung Cancer Conference, Nov. 30, Offers Medical and Patient Education, Advocacy and Survivor's Perspective 5Health News:BREATHE Lung Cancer Conference, Nov. 30, Offers Medical and Patient Education, Advocacy and Survivor's Perspective 6Health News:New research helps explain how tumors go undetected by the body 2Health News:High Blood Pressure Linked to Disability, Dementia 2Health News:High Blood Pressure Linked to Disability, Dementia 3
... portable NEVA™ System is designed ... changes within the penis nocturnally. ... to monitor and record impedance ... changes in penile blood volume. ...
... designed for vascular labs already equipped ... Its primary use will be for ... cuff with air. Blood pressures ... - a proximal occluding cuff connected ...
... your patients come to you with ... they can understand. Then they want ... Rigidity Assessment System can you gather, ... rigidity and tumescence data...and provide the ...
... The table top design takes into ... and creates a flexible working environment for ... the alphamaxx can be matched exactly to ... top slide capability creates superior access for ...
Medicine Products: